“The Report Multiple Myeloma – Japan Drug Forecast and Market Analysis to 2023 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz”
The Multiple Myeloma (MM) market is currently dominated by Velcade and Revlimid, and the market is set to undergo substantial growth between 2013 and 2023. The main drivers of growth will be the launch of monoclonal antibodies (mAbs) Empliciti and daratumumab, which will not only provide a new treatment option for MM patients, but will also lengthen the time between relapses, meaning that the duration of Revlimid and/or Velcade treatments will also be longer. Furthermore, the relatively mild safety profile of these mAbs and the significant efficacies demonstrated by these agents will mean that more MM patients will ultimately receive drug treatment. Label extensions of these mAbs, as well as of second-generation proteasome inhibitors ixazomib and Kyprolis, will further increase treatment options for these patients. The biggest constrainers of the MM market are the increasing cost-consciousness of healthcare providers, as the launch and subsequent label extensions of these pipeline agents will lead to a significant expense, which may impact uptake of these drugs. The patent expiries of Revlimid and Velcade will somewhat alleviate healthcare spending on multiple myeloma patients, which may assist in the uptake of mAbs and second-generation PIs in the multiple myeloma market.
Japan will experience significant market growth, driven by the uptake of the latest premium-priced therapies. KOLs identified the reimbursement of drugs in Japan as a significant barrier to market growth, although oncology drugs are generally reimbursed if they demonstrate clinically significant efficacy.
To Get Free Sample Copy Of this Report At http://www.marketresearchreports.biz/sample/sample/805608
Overview of Multiple Myeloma including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
– Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
– Sales forecast for the top drugs in Japan from 2014-2024.
– Analysis of the impact of key events as well the drivers and restraints affecting Japan Multiple Myeloma market.
Reasons to buy
– Understand and capitalize by identifying products that are most likely to ensure a robust return
– Stay ahead of the competition by understanding the changing competitive landscape for Multiple Myeloma.
– Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
– Make more informed business decisions from insightful and in-depth analysis of drug performance
– Obtain sales forecast for drugs from 2014-2024 in Japan.
Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreports-biz
Table of Content
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 10
2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 12
2.3 Upcoming Related Reports 12
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 13
3.2 Staging Systems 16
3.3 Response and Relapse Criteria 17
3.4 Symptoms 19
3.5 Prognosis 20
3.6 Quality of Life 21
4 Disease Management 24
4.1 Treatment Overview 24
4.2 Diagnosis 25
4.3 Clinical Practice 26
4.3.1 Primary Therapy for SCT-Eligible Patients 27
4.3.2 Primary Therapy for Non-SCT Patients 29
4.3.3 Salvage/Relapse Therapy 30
4.3.4 Leading Prescribed Drugs 31
4.4 Japan 34
4.4.1 Diagnosis 35
4.4.2 Clinical Practice 35
5 Competitive Assessment 37
5.1 Overview 37
5.2 Product Profiles – Proteasome Inhibitors 37
5.2.1 Velcade (Bortezomib) 37
5.2.2 Kyprolis (Carfilzomib) 44
5.3 Product Profiles – Immunomodulators 52
5.3.1 Revlimid (Lenalidomide) 52
5.3.2 Pomalyst/Imnovid (Pomalidomide) 59
5.4 Other Therapeutic Classes 64
6 Unmet Need and Opportunity 65
6.1 Overview 65
6.2 Treatment of High-Risk Patients 65
6.2.1 Unmet Need 65
6.2.2 Gap Analysis 66
6.2.3 Opportunity 67
6.3 Treatment of Patients with Smoldering Myeloma 67
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
90 Sate Street, Suite 700
Albany, NY 12207